Overview

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney stones.
Phase:
Phase 2
Details
Lead Sponsor:
Allena Pharmaceuticals